MX2010014222A - Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson. - Google Patents

Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.

Info

Publication number
MX2010014222A
MX2010014222A MX2010014222A MX2010014222A MX2010014222A MX 2010014222 A MX2010014222 A MX 2010014222A MX 2010014222 A MX2010014222 A MX 2010014222A MX 2010014222 A MX2010014222 A MX 2010014222A MX 2010014222 A MX2010014222 A MX 2010014222A
Authority
MX
Mexico
Prior art keywords
parkinson
disease
combinations
treatment
modulator
Prior art date
Application number
MX2010014222A
Other languages
English (en)
Spanish (es)
Inventor
Gasparini Fabrizio
Gomez-Mancilla Baltazar
Original Assignee
Novartis Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag Star filed Critical Novartis Ag Star
Publication of MX2010014222A publication Critical patent/MX2010014222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010014222A 2008-06-30 2009-06-30 Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson. MX2010014222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7677208P 2008-06-30 2008-06-30
PCT/EP2009/058230 WO2010000763A2 (fr) 2008-06-30 2009-06-30 Produits de combinaison

Publications (1)

Publication Number Publication Date
MX2010014222A true MX2010014222A (es) 2011-03-29

Family

ID=41112516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014222A MX2010014222A (es) 2008-06-30 2009-06-30 Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.

Country Status (11)

Country Link
US (2) US8703809B2 (fr)
EP (2) EP2826478A1 (fr)
JP (1) JP2011526596A (fr)
KR (1) KR20110027817A (fr)
CN (2) CN103212078A (fr)
AU (1) AU2009265760B2 (fr)
BR (1) BRPI0913642A2 (fr)
CA (1) CA2729595C (fr)
MX (1) MX2010014222A (fr)
RU (1) RU2496494C2 (fr)
WO (1) WO2010000763A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ584856A (en) * 2007-10-12 2012-12-21 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of parkinson's disease
US8084487B2 (en) * 2008-08-12 2011-12-27 Novartis Ag Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof
EP2655326A1 (fr) * 2010-12-20 2013-10-30 Novartis AG Esters d'acides 4-(hétéro)aryl-éthynyl-octahydro-indole-1-carboxyliques
GB201204962D0 (en) 2012-03-21 2012-05-02 Addex Pharmaceuticals Sa Pharmaceutical combination products for parkinsons disease
JP5744112B2 (ja) * 2013-06-11 2015-07-01 デクセリアルズ株式会社 パターン形成体の製造方法
BR112016024502A8 (pt) * 2014-04-21 2021-06-29 Civitas Therapeutics Inc uso de uma dose de partículas finas (fdp) de levodopa na fabricação de um medicamento
WO2019025932A1 (fr) * 2017-07-31 2019-02-07 Novartis Ag Utilisation de mavoglurant dans la réduction de l'utilisation d'alcool ou dans la prévention de rechute dans l'utilisation d'alcool
KR20200035035A (ko) * 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
US5521297A (en) 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CN101723941A (zh) 2002-08-09 2010-06-09 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑
AU2003267087A1 (en) * 2002-09-13 2004-04-30 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
US7393959B2 (en) 2003-04-04 2008-07-01 Merck & Co. Inc. Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
WO2005030128A2 (fr) * 2003-09-23 2005-04-07 Merck & Co., Inc. Modulateurs pyrazole de recepteurs de glutamate metabotropiques
CA2549969A1 (fr) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
EP1677789A1 (fr) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
WO2005044265A1 (fr) 2003-10-31 2005-05-19 Astrazeneca Ab Alcynes iii
WO2005079802A1 (fr) 2004-02-12 2005-09-01 Merck & Co., Inc. Amides bipyridyles en tant que modulateurs du récepteur-5 métabotropique du glutamate
US20060059561A1 (en) 2004-04-14 2006-03-16 Digital River, Inc. Electronic storefront that limits download of software wrappers based on geographic location
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
BRPI0620066A2 (pt) 2005-12-20 2011-11-01 Novartis Ag derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
US7777031B2 (en) 2006-05-30 2010-08-17 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
EA014576B1 (ru) * 2006-06-16 2010-12-30 Солвей Фармасьютикалс Б.В. Комбинированные препараты, содержащие бифепрунокс и l-допу
AR063680A1 (es) * 2006-08-04 2009-02-11 Merz Pharma Gmbh & Co Kgaa Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
WO2008031550A2 (fr) 2006-09-11 2008-03-20 Novartis Ag Nouvelles utilisations de récepteurs de glutamate métabotropiques
NZ584856A (en) * 2007-10-12 2012-12-21 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of parkinson's disease

Also Published As

Publication number Publication date
EP2320892A2 (fr) 2011-05-18
AU2009265760A1 (en) 2010-01-07
AU2009265760B2 (en) 2013-07-18
US20140194423A1 (en) 2014-07-10
CN102131503A (zh) 2011-07-20
CA2729595C (fr) 2017-01-03
WO2010000763A3 (fr) 2010-02-25
JP2011526596A (ja) 2011-10-13
EP2826478A1 (fr) 2015-01-21
RU2496494C2 (ru) 2013-10-27
WO2010000763A2 (fr) 2010-01-07
BRPI0913642A2 (pt) 2015-11-24
KR20110027817A (ko) 2011-03-16
US20120122878A1 (en) 2012-05-17
RU2011103083A (ru) 2012-08-10
CA2729595A1 (fr) 2010-01-07
US8703809B2 (en) 2014-04-22
CN103212078A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
MX2010014222A (es) Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
PH12017500930A1 (en) Hsp90 inhibitor combinations
MXPA05010873A (es) Metodos para el tratamiento de enfermedad de parkinson.
EP4299128A3 (fr) Compositions d'inhibiteurs de dopa-décarboxylase
WO2008097525A3 (fr) Inhibition locale de complément destinée au traitement de troubles induits par le complément
NO20064792L (no) Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
TN2010000155A1 (en) Organic compounds
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
TN2009000381A1 (en) C5 antigens and uses thereof
MX2009004038A (es) Gel de diclofenaco.
CR20110206A (es) Método de uso de una sepa de bacillus subtilis para mejorar la salud de animales
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
BRPI0709965C2 (pt) formulações melhoradas de poliamina para a iontoforese do composto triptano
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
WO2010021693A3 (fr) Modulateurs de mif
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
TW200639180A (en) PYY agonists and uses thereof
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
MX2009008364A (es) Sal de napadisilato de un antagonista m3 muscarinico.
MX2009011712A (es) Formulaciones mejoradas de lamotrigina.
EP2257153A4 (fr) Semelle destinée à être utilisée sur des sabots et fer comprenant ladite semelle
MY152546A (en) A non-reusable circumcision clamp
MX2009008191A (es) Medicamento para el tratamiento de endometriosis.
EP3891122A4 (fr) Inhibiteurs de décarboxylase pour le traitement de la maladie de parkinson

Legal Events

Date Code Title Description
FA Abandonment or withdrawal